Literature DB >> 4014283

Hip implant infection. Treatment with resection arthroplasty and late total hip arthroplasty.

R H Fitzgerald, D R Jones.   

Abstract

In 131 patients with an infected hip implant, treatment was surgical excision of the implant (resection arthroplasty) and delayed reconstruction with a total hip arthroplasty. Most of the patients had low-grade infections: only 5 percent had a temperature of 37.8 degrees C or higher and only 20 percent had wound drainage. Hip pain was the primary symptom of a deep infection in 90 percent. Staphylococci were the most frequently isolated causal organisms, recovered from deep tissue specimens in 84 patients. The hip was reconstructed six days to 32 years (mode, 429 days) after resection arthroplasty. At follow-up two to nine years after reconstruction, 88 percent of the 131 patients were free of infection. Recurrent sepsis was more common (p less than 0.05) in patients with incomplete acrylic cement removal or patients in whom reconstruction was performed less than 429 days after resection arthroplasty. Risk of recurrent sepsis was increased when gram-negative bacilli in pure or mixed cultures were found, but the difference was not statistically significant.

Entities:  

Mesh:

Year:  1985        PMID: 4014283     DOI: 10.1016/0002-9343(85)90389-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

Review 1.  [Guidelines on antimicrobial therapy in situations of periprosthetic THR infection].

Authors:  L Frommelt
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

2.  Pathogenesis and prevention of biomaterial centered infections.

Authors:  B Gottenbos; H J Busscher; H C Van Der Mei; P Nieuwenhuis
Journal:  J Mater Sci Mater Med       Date:  2002-08       Impact factor: 3.896

3.  [One stage revision of infected total hip replacements with replacement of bone loss by allografts. Study of 90 cases of which 46 used bone allografts].

Authors:  B Loty; M Postel; J Evrard; P Matron; J P Courpied; M Kerboull; B Tomeno
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

4.  Bone and joint infections.

Authors:  T Louie
Journal:  Can J Infect Dis       Date:  1992-03

Review 5.  Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins.

Authors:  L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Brucellar prosthetic arthritis in a total knee replacement.

Authors:  A Ortí; P Roig; R Alcalá; V Navarro; M Salavert; C Martín; A Zorraquino; J Merino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

7.  Purification and characterization of the staphylococcal slime-associated antigen and its occurrence among Staphylococcus epidermis clinical isolates.

Authors:  L Baldassarri; G Donnelli; A Gelosia; M C Voglino; A W Simpson; G D Christensen
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

8.  Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).

Authors:  A Stein; J F Bataille; M Drancourt; G Curvale; J N Argenson; P Groulier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 9.  What is the evidence base to guide surgical treatment of infected hip prostheses? systematic review of longitudinal studies in unselected patients.

Authors:  Andrew D Beswick; Karen T Elvers; Alison J Smith; Rachael Gooberman-Hill; Andrew Lovering; Ashley W Blom
Journal:  BMC Med       Date:  2012-02-16       Impact factor: 8.775

10.  In vitro interactions between bacteria, osteoblast-like cells and macrophages in the pathogenesis of biomaterial-associated infections.

Authors:  Guruprakash Subbiahdoss; Isabel C Saldarriaga Fernández; Joana F da Silva Domingues; Roel Kuijer; Henny C van der Mei; Henk J Busscher
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.